|
EMA Guideline Recommends Placebo Arms for Short-Term Trials of Schizophrenia Drugs
The European Medicines Agency (EMA) is advising sponsors to use placebo arms, rather than active comparators, in short-term trials of schizophrenia drugs, according to a final guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives